$SGMO
Sangamo Therapeutics Inc

2014 Q3 Form 10-Q Financial Statement

#000119312514284673 Filed on July 29, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $12.42M $10.39M $6.934M
YoY Change 117.57% 49.77% 51.6%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.730M $3.970M $3.120M
YoY Change 18.04% 27.24% 13.87%
% of Gross Profit
Research & Development $16.29M $13.46M $9.278M
YoY Change 87.18% 45.07% 22.56%
% of Gross Profit
Depreciation & Amortization $100.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 100.0%
% of Gross Profit
Operating Expenses $20.07M $17.43M $12.40M
YoY Change 69.15% 40.56% 20.2%
Operating Profit -$5.468M
YoY Change
Interest Expense $110.0K $70.00K $20.00K
YoY Change 1000.0% 250.0% 0.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$7.545M -$6.980M -$5.450M
YoY Change 22.68% 28.07% -4.89%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.545M -$6.981M -$5.450M
YoY Change 22.78% 28.09% -4.85%
Net Earnings / Revenue -60.76% -67.22% -78.6%
Basic Earnings Per Share
Diluted Earnings Per Share -$110.7K -$102.7K -$101.3K
COMMON SHARES
Basic Shares Outstanding 68.16M shares 67.96M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $162.4M $193.7M $47.30M
YoY Change 35.11% 309.51% -20.64%
Cash & Equivalents $11.21M $99.27M $12.05M
Short-Term Investments $151.2M $94.40M $35.20M
Other Short-Term Assets $887.0K $671.0K $1.300M
YoY Change 495.3% -48.38% 116.67%
Inventory
Prepaid Expenses $751.0K $1.053M
Receivables $8.474M $6.969M $4.900M
Other Receivables $300.0K $300.0K $300.0K
Total Short-Term Assets $173.2M $203.0M $53.70M
YoY Change 37.28% 277.99% -15.7%
LONG-TERM ASSETS
Property, Plant & Equipment $1.566M $1.622M $1.600M
YoY Change 4.82% 1.38% 6.67%
Goodwill $1.585M $1.585M
YoY Change
Intangibles
YoY Change
Long-Term Investments $69.00M $42.70M $18.80M
YoY Change 443.31% 127.13% -10.9%
Other Assets $108.0K $0.00 $0.00
YoY Change
Total Long-Term Assets $74.18M $47.86M $20.50M
YoY Change 421.54% 133.45% -9.29%
TOTAL ASSETS
Total Short-Term Assets $173.2M $203.0M $53.70M
Total Long-Term Assets $74.18M $47.86M $20.50M
Total Assets $247.3M $250.8M $74.20M
YoY Change 76.22% 238.06% -14.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.000M $5.700M $3.300M
YoY Change 196.3% 72.73% 26.92%
Accrued Expenses $2.700M $2.000M $1.400M
YoY Change 35.0% 42.86% 7.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.49M $16.80M $7.100M
YoY Change 178.33% 136.61% 14.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $17.00M $18.90M $7.800M
YoY Change 136.11% 142.31% -21.21%
Total Long-Term Liabilities $17.00M $18.90M $7.800M
YoY Change 136.11% 142.31% -21.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.49M $16.80M $7.100M
Total Long-Term Liabilities $17.00M $18.90M $7.800M
Total Liabilities $37.21M $36.48M $14.80M
YoY Change 161.57% 146.49% -8.07%
SHAREHOLDERS EQUITY
Retained Earnings -$324.2M -$316.7M
YoY Change 10.29%
Common Stock $534.3M $681.0K
YoY Change 86922.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $210.1M $214.4M $59.40M
YoY Change
Total Liabilities & Shareholders Equity $247.3M $250.8M $74.20M
YoY Change 76.22% 238.06% -14.02%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$7.545M -$6.981M -$5.450M
YoY Change 22.78% 28.09% -4.85%
Depreciation, Depletion And Amortization $100.0K $200.0K $200.0K
YoY Change 0.0% 0.0% 100.0%
Cash From Operating Activities -$5.800M -$8.600M -$5.300M
YoY Change 28.89% 62.26% -11.67%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$400.0K -$200.0K
YoY Change 0.0% 100.0% 100.0%
Acquisitions
YoY Change
Other Investing Activities -$83.40M -$20.40M $3.600M
YoY Change -6515.38% -666.67% -1000.0%
Cash From Investing Activities -$83.40M -$20.80M $3.200M
YoY Change -6515.38% -750.0% -1166.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.200M 1.700M 1.900M
YoY Change -98.32% -10.53% 375.0%
NET CHANGE
Cash From Operating Activities -5.800M -8.600M -5.300M
Cash From Investing Activities -83.40M -20.80M 3.200M
Cash From Financing Activities 1.200M 1.700M 1.900M
Net Change In Cash -88.00M -27.70M -200.0K
YoY Change -228.84% 13750.0% -96.61%
FREE CASH FLOW
Cash From Operating Activities -$5.800M -$8.600M -$5.300M
Capital Expenditures -$100.0K -$400.0K -$200.0K
Free Cash Flow -$5.700M -$8.200M -$5.100M
YoY Change 29.55% 60.78% -13.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68164413 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12052000
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68101479 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68101479 shares
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
748000
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
530329000
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16799000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
33000
CY2014Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1650000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
214357000
CY2014Q2 us-gaap Liabilities
Liabilities
36480000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
681000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
250837000
CY2014Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1973000
CY2014Q2 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1650000
CY2014Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5709000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316686000
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8842000
CY2014Q2 sgmo Available For Sale Securities Gross Unrealized Gains Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainsAccumulatedInInvestments
34000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
12000
CY2014Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
17283000
CY2014Q2 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1650000
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
94386000
CY2014Q2 us-gaap Assets Current
AssetsCurrent
202980000
CY2014Q2 us-gaap Goodwill
Goodwill
1585000
CY2014Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
229317000
CY2014Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
42741000
CY2014Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
320000
CY2014Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1053000
CY2014Q2 us-gaap Assets
Assets
250837000
CY2014Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
229350000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99270000
CY2014Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6969000
CY2014Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1870000
CY2014Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
229350000
CY2014Q2 us-gaap Other Assets
OtherAssets
39000
CY2014Q2 us-gaap Other Assets Current
OtherAssetsCurrent
671000
CY2014Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
311000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1622000
CY2014Q2 sgmo Escrow Liability
EscrowLiability
275000
CY2014Q2 sgmo Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
1000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21679000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
62243892 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
62243892 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
748000
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
423209000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10131000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1570000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
121710000
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3194000
CY2013Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
1570000
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4380000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-302133000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2282000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
622000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140838000
CY2013Q4 us-gaap Liabilities
Liabilities
19128000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6679000
CY2013Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1570000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
82627000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
27524000
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
27420000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
97274000
CY2013Q4 us-gaap Goodwill
Goodwill
1585000
CY2013Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
38663000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
320000
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
457000
CY2013Q4 us-gaap Assets
Assets
140838000
CY2013Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
128224000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10186000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3155000
CY2013Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
1870000
CY2013Q4 us-gaap Other Assets
OtherAssets
40000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
191000
CY2013Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
338000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1406000
CY2013Q4 sgmo Escrow Liability
EscrowLiability
275000
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2 Program
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53583000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13311000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8344138 shares
us-gaap Revenues
Revenues
11557000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
753000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12362000
us-gaap Investment Income Interest
InvestmentIncomeInterest
38000
us-gaap Revenue From Grants
RevenueFromGrants
1317000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12373000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
83000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
789000
us-gaap Net Income Loss
NetIncomeLoss
-12335000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
349000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-27000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1030000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6432000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4137000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1070000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-719000
us-gaap Share Based Compensation
ShareBasedCompensation
2707000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9627000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-453000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4137000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17498000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
305000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2707000
us-gaap Operating Expenses
OperatingExpenses
23930000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
456000
sgmo Collaboration Agreements
CollaborationAgreements
10240000
dei Trading Symbol
TradingSymbol
SGMO
dei Entity Registrant Name
EntityRegistrantName
SANGAMO BIOSCIENCES INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001001233
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1076000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14532000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
67003000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65603000 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2805000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
80000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"> <b><i>Use of Estimates and Classifications</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value measurements, business combinations including the fair value of the contingent consideration liability for payments to former Ceregene Inc. (Ceregene) stockholders and intangible assets related to the acquisition of Ceregene, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</p> </div>
us-gaap Revenues
Revenues
18501000
sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P1Y
CY2013Q2 us-gaap Revenue From Grants
RevenueFromGrants
777000
us-gaap Investment Income Interest
InvestmentIncomeInterest
105000
us-gaap Revenue From Grants
RevenueFromGrants
1212000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14658000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-27000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3814000
us-gaap Net Income Loss
NetIncomeLoss
-14553000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
465000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
21000
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
50604000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1221000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7616000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
80000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
103143000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
17164000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1329000
us-gaap Share Based Compensation
ShareBasedCompensation
4036000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
89084000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-16864000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9347000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25463000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
250000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4036000
us-gaap Operating Expenses
OperatingExpenses
33159000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
583000
sgmo Collaboration Agreements
CollaborationAgreements
17289000
sgmo Proceeds From Issuance Initial Public Offering Net Of Costs
ProceedsFromIssuanceInitialPublicOfferingNetOfCosts
93796000
CY2013 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53786000 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2013Q2 us-gaap Revenues
Revenues
6934000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5476000
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
18000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5468000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-5450000
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-26000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3124000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9278000
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1378000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
12402000
CY2013Q2 sgmo Collaboration Agreements
CollaborationAgreements
6157000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67980000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7243724 shares
us-gaap Revenues
Revenues
10385000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6969000
us-gaap Investment Income Interest
InvestmentIncomeInterest
66000
us-gaap Revenue From Grants
RevenueFromGrants
664000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7047000
us-gaap Net Income Loss
NetIncomeLoss
-6981000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
12000
us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3972000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
30000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13430000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2129000
us-gaap Operating Expenses
OperatingExpenses
17432000
sgmo Collaboration Agreements
CollaborationAgreements
9721000

Files In Submission

Name View Source Status
0001193125-14-284673-index-headers.html Edgar Link pending
0001193125-14-284673-index.html Edgar Link pending
0001193125-14-284673.txt Edgar Link pending
0001193125-14-284673-xbrl.zip Edgar Link pending
d748320d10q.htm Edgar Link pending
d748320dex311.htm Edgar Link pending
d748320dex312.htm Edgar Link pending
d748320dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-20140630.xml Edgar Link completed
sgmo-20140630.xsd Edgar Link pending
sgmo-20140630_cal.xml Edgar Link unprocessable
sgmo-20140630_def.xml Edgar Link unprocessable
sgmo-20140630_lab.xml Edgar Link unprocessable
sgmo-20140630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending